All In Biotech

Drug Trial Radar · NCT03732807

PF-06651600 for the Treatment of Alopecia Areata

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS

Last checked: Nov 20, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 718 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

718

Actual

Start

Dec 3, 2018

Primary completion

Dec 31, 2020

Study completion Jun 24, 2021

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

Conditions

  • Alopecia Areata

Interventions

  • PF-06651600 Induction DoseDrug

    Oral tablets taken once daily (QD)

  • PF-06651600 Maintenance Dose #1Drug

    Oral tablets taken QD

  • PF-06651600 Maintenance Dose #2Drug

    Oral tablets taken QD

  • PF-06651600 Maintenance Dose #3Drug

    Oral tablets taken QD

  • PlaceboDrug

    Oral tablets taken QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24Time frame: Week 24

Locations

155 sites in 18 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham Hospital Outreach Lab

    Birmingham, Alabama

  • The University of Alabama at Birmingham, Department of Dermatology

    Birmingham, Alabama

  • The University of Alabama at Birmingham, Department of Dermatology

    Birmingham, Alabama

  • Mosaic Dermatology

    Beverly Hills, California

  • University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center

    Irvine, California

  • Dermatology Specialists, Inc.

    Murrieta, California

  • University of California, San Francisco

    San Francisco, California

  • Kaiser Permanente Clinical Trials Unit

    San Francisco, California

  • Southern California Dermatology, Inc.

    Santa Ana, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • University of Colorado Hospital Clinical and Translational Research Center

    Aurora, Colorado

  • University of Colorado Hospital Outpatient Pavillion

    Aurora, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • Church Street Research Unit

    New Haven, Connecticut

  • Medstar Georgetown University Hospital Center-Department of Otolaryngology

    Washington D.C., District of Columbia

  • Medstar Washington Hospital Center-Claude Nogay Research Pharmacy

    Washington D.C., District of Columbia

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia

  • Medstar Georgetown University Hospital Center-Department of Pediatrics

    Washington D.C., District of Columbia

  • Siperstein Dermatology Group

    Boynton Beach, Florida

  • Park Avenue Dermatology

    Orange Park, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Advanced Clinical Research

    Meridian, Idaho

  • Northwestern Medical Group

    Chicago, Illinois

  • Northwestern Medicine Diagnostic Testing Center

    Chicago, Illinois

  • Northwestern Medicine

    Chicago, Illinois

  • Northwestern Memorial Hospital, Investigational Research Pharmacy

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • NorthShore University HealthSystem

    Skokie, Illinois

  • Southern Illinois University School of Medicine

    Springfield, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics; Department of Pharmacy-IDS;

    Iowa City, Iowa

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Medstar Georgetown University Hospital - Department of Dermatology

    Chevy Chase, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Minnesota Department of Dermatology

    Minneapolis, Minnesota

  • University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke

    Minneapolis, Minnesota

  • Skin Specialists, PC

    Omaha, Nebraska

  • The Dermatology Group, P.C.

    Verona, New Jersey

  • NYU School of Medicine, The Ronald O. Perelman Department of Dermatology

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

Showing 40 of 155 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.